Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page now displays a new revision tag: Revision: v3.5.4. The previous revision tag Revision: v3.5.3 has been removed.
    Difference
    0.1%
    Check dated 2026-05-16T09:28:47.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a change in the site release rather than study details.
    Difference
    0.1%
    Check dated 2026-04-24T22:23:53.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T13:49:13.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-19T23:52:08.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Updated the page revision from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-12T20:24:10.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    The page now shows revision v3.4.2, replacing the previous v3.4.1. This is a minor metadata update that does not affect content, functionality, or user interactions.
    Difference
    0.1%
    Check dated 2026-02-12T01:40:03.000Z thumbnail image

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.